Showing results (221-230 of 245) with videos related to
Sort By:
Pageof 25
Diabetologia|April 24, 2010
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individualsA Zanchi, M Maillard, F R Jornayvaz, et al.Hypertension (Dallas, Tex. : 1979)|February 19, 1999
Adducin polymorphism affects renal proximal tubule reabsorption in hypertensionP Manunta, M Burnier, M D'Amico, et al.Obstetrics and Gynecology|April 1, 1984
Estradiol, estrone, and gonadotropin levels after use of vaginal estradiolP L Martin, M O Greaney, A M Burnier, et al.Journal of Hypertension|October 11, 2001
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and goutG Würzner, J C Gerster, A Chiolero, et al.Journal of Hypertension|April 29, 1998
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patientsA Pechère-Bertschi, J Nussberger, L Decosterd, et al.Renal Failure|May 9, 1998
Estimation of glomerular filtration rate by sinistrin clearance using various approachesT Buclin, R Sechaud, A P Bertschi, et al.Kidney International|October 10, 1998
Circadian variations of renal sodium handling in patients with orthostatic hypotensionA Pechère-Bertschi, J Nussberger, J Biollaz, et al.Clinical Pharmacology and Therapeutics|August 1, 1991
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteersM Burnier, M Ganslmayer, F Perret, et al.Hypertension (Dallas, Tex. : 1979)|November 22, 1997
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humansR Weber, A Pechère-Bertschi, D Hayoz, et al.Rheumatology (Oxford, England)|October 18, 2000
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenonD Hayoz, G Bizzini, B Noël, et al.Pageof 25